WHO's antibacterial pipeline reports
Despite this attention from WHO, global pharmaceutical companies focusing on antibiotic development have given up their treasure hunt for new candidates, returning to antimicrobials only because of COVID-19. To Noonan, there are two sub-factors: the timing between medicine administration and cure, a...
Gespeichert in:
| Veröffentlicht in: | The Lancet infectious diseases 2022-10, Vol.22 (10), p.1424-1424 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1424 |
|---|---|
| container_issue | 10 |
| container_start_page | 1424 |
| container_title | The Lancet infectious diseases |
| container_volume | 22 |
| creator | Balakrishnan, Vijay Shankar |
| description | Despite this attention from WHO, global pharmaceutical companies focusing on antibiotic development have given up their treasure hunt for new candidates, returning to antimicrobials only because of COVID-19. To Noonan, there are two sub-factors: the timing between medicine administration and cure, and the cost of production versus sale. For more on the AMR Action Fund see https://www.amractionfund.com/ For the WHO priority pathogens list see https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed For WHO's antibacterial pipeline report see https://www.who.int/publications/i/item/9789240047655 For WHO's bacterial vaccine pipeline report see https://www.who.int/publications/i/item/9789240052451 |
| doi_str_mv | 10.1016/S1473-3099(22)00603-X |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2717698271</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2716495790</sourcerecordid><originalsourceid>FETCH-LOGICAL-c361t-beac3ae756cd5dfa16ac9dee07da7827b85cfae7066bf2dced63d0f85832fed73</originalsourceid><addsrcrecordid>eNpdkMFKxDAQhoMouK4-glBQcD1UJ0mTtEdZ1BUW9qDi3kKaTKBLt61J9-Db23Y9eZph_o-f4SPkmsIDBSof32mmeMqhKBaM3QNI4On2hMyGc5ZmmVCn035EzslFjDsAqihkM3L7tdrcxcQ0fVUa22OoTJ10VYd11WASsGtDHy_JmTd1xKu_OSefL88fy1W63ry-LZ_WqeWS9mmJxnKDSkjrhPOGSmMLhwjKGZUzVebC-iEHKUvPnEUnuQOfi5wzj07xOVkce7vQfh8w9npfRYt1bRpsD1EzRZUshiY6oDf_0F17CM3w3UjJrBCqgIESR8qGNsaAXneh2pvwoyno0Z2e3OlRjGZMT-70lv8CkMVhmg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2716495790</pqid></control><display><type>article</type><title>WHO's antibacterial pipeline reports</title><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Balakrishnan, Vijay Shankar</creator><creatorcontrib>Balakrishnan, Vijay Shankar</creatorcontrib><description>Despite this attention from WHO, global pharmaceutical companies focusing on antibiotic development have given up their treasure hunt for new candidates, returning to antimicrobials only because of COVID-19. To Noonan, there are two sub-factors: the timing between medicine administration and cure, and the cost of production versus sale. For more on the AMR Action Fund see https://www.amractionfund.com/ For the WHO priority pathogens list see https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed For WHO's antibacterial pipeline report see https://www.who.int/publications/i/item/9789240047655 For WHO's bacterial vaccine pipeline report see https://www.who.int/publications/i/item/9789240052451</description><identifier>ISSN: 1473-3099</identifier><identifier>EISSN: 1474-4457</identifier><identifier>DOI: 10.1016/S1473-3099(22)00603-X</identifier><language>eng</language><publisher>London: Elsevier Limited</publisher><subject>Antibiotics ; Antiinfectives and antibacterials ; Antimicrobial agents ; COVID-19 ; Drug resistance ; Immunization ; Infectious diseases ; Pathogens ; Pharmaceutical industry ; R&D ; Research & development ; Vaccines</subject><ispartof>The Lancet infectious diseases, 2022-10, Vol.22 (10), p.1424-1424</ispartof><rights>2022. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c361t-beac3ae756cd5dfa16ac9dee07da7827b85cfae7066bf2dced63d0f85832fed73</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2716495790?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,64385,64387,64389,72469</link.rule.ids></links><search><creatorcontrib>Balakrishnan, Vijay Shankar</creatorcontrib><title>WHO's antibacterial pipeline reports</title><title>The Lancet infectious diseases</title><description>Despite this attention from WHO, global pharmaceutical companies focusing on antibiotic development have given up their treasure hunt for new candidates, returning to antimicrobials only because of COVID-19. To Noonan, there are two sub-factors: the timing between medicine administration and cure, and the cost of production versus sale. For more on the AMR Action Fund see https://www.amractionfund.com/ For the WHO priority pathogens list see https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed For WHO's antibacterial pipeline report see https://www.who.int/publications/i/item/9789240047655 For WHO's bacterial vaccine pipeline report see https://www.who.int/publications/i/item/9789240052451</description><subject>Antibiotics</subject><subject>Antiinfectives and antibacterials</subject><subject>Antimicrobial agents</subject><subject>COVID-19</subject><subject>Drug resistance</subject><subject>Immunization</subject><subject>Infectious diseases</subject><subject>Pathogens</subject><subject>Pharmaceutical industry</subject><subject>R&D</subject><subject>Research & development</subject><subject>Vaccines</subject><issn>1473-3099</issn><issn>1474-4457</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkMFKxDAQhoMouK4-glBQcD1UJ0mTtEdZ1BUW9qDi3kKaTKBLt61J9-Db23Y9eZph_o-f4SPkmsIDBSof32mmeMqhKBaM3QNI4On2hMyGc5ZmmVCn035EzslFjDsAqihkM3L7tdrcxcQ0fVUa22OoTJ10VYd11WASsGtDHy_JmTd1xKu_OSefL88fy1W63ry-LZ_WqeWS9mmJxnKDSkjrhPOGSmMLhwjKGZUzVebC-iEHKUvPnEUnuQOfi5wzj07xOVkce7vQfh8w9npfRYt1bRpsD1EzRZUshiY6oDf_0F17CM3w3UjJrBCqgIESR8qGNsaAXneh2pvwoyno0Z2e3OlRjGZMT-70lv8CkMVhmg</recordid><startdate>20221001</startdate><enddate>20221001</enddate><creator>Balakrishnan, Vijay Shankar</creator><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20221001</creationdate><title>WHO's antibacterial pipeline reports</title><author>Balakrishnan, Vijay Shankar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c361t-beac3ae756cd5dfa16ac9dee07da7827b85cfae7066bf2dced63d0f85832fed73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antibiotics</topic><topic>Antiinfectives and antibacterials</topic><topic>Antimicrobial agents</topic><topic>COVID-19</topic><topic>Drug resistance</topic><topic>Immunization</topic><topic>Infectious diseases</topic><topic>Pathogens</topic><topic>Pharmaceutical industry</topic><topic>R&D</topic><topic>Research & development</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Balakrishnan, Vijay Shankar</creatorcontrib><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Balakrishnan, Vijay Shankar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>WHO's antibacterial pipeline reports</atitle><jtitle>The Lancet infectious diseases</jtitle><date>2022-10-01</date><risdate>2022</risdate><volume>22</volume><issue>10</issue><spage>1424</spage><epage>1424</epage><pages>1424-1424</pages><issn>1473-3099</issn><eissn>1474-4457</eissn><abstract>Despite this attention from WHO, global pharmaceutical companies focusing on antibiotic development have given up their treasure hunt for new candidates, returning to antimicrobials only because of COVID-19. To Noonan, there are two sub-factors: the timing between medicine administration and cure, and the cost of production versus sale. For more on the AMR Action Fund see https://www.amractionfund.com/ For the WHO priority pathogens list see https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed For WHO's antibacterial pipeline report see https://www.who.int/publications/i/item/9789240047655 For WHO's bacterial vaccine pipeline report see https://www.who.int/publications/i/item/9789240052451</abstract><cop>London</cop><pub>Elsevier Limited</pub><doi>10.1016/S1473-3099(22)00603-X</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1473-3099 |
| ispartof | The Lancet infectious diseases, 2022-10, Vol.22 (10), p.1424-1424 |
| issn | 1473-3099 1474-4457 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2717698271 |
| source | Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | Antibiotics Antiinfectives and antibacterials Antimicrobial agents COVID-19 Drug resistance Immunization Infectious diseases Pathogens Pharmaceutical industry R&D Research & development Vaccines |
| title | WHO's antibacterial pipeline reports |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T03%3A09%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=WHO's%20antibacterial%20pipeline%20reports&rft.jtitle=The%20Lancet%20infectious%20diseases&rft.au=Balakrishnan,%20Vijay%20Shankar&rft.date=2022-10-01&rft.volume=22&rft.issue=10&rft.spage=1424&rft.epage=1424&rft.pages=1424-1424&rft.issn=1473-3099&rft.eissn=1474-4457&rft_id=info:doi/10.1016/S1473-3099(22)00603-X&rft_dat=%3Cproquest_cross%3E2716495790%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2716495790&rft_id=info:pmid/&rfr_iscdi=true |